Intraocular injection of 0.3 ml C3F8 gas for the treatment of patients with vitreomacular traction

Outcome after gas injection for the treatment of vitreomacular traction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10482807

Enrollment

Registered

2017-10-04

Start date

2017-10-01

Completion date

Unknown

Last updated

2021-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with symptomatic vitreomacular traction Eye Diseases Patients with symptomatic vitreomacular traction

Interventions

Patients with symptomatic vitreomacular traction are included in this study. This procedure is performed by an experienced surgeon. The intervention takes about 10 minutes. Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All patients with a symptomatic vitreomacular traction 2. Aged 18 and older

Exclusion criteria

Exclusion criteria: 1. Presence of Epiretinal Membrane over the macula at baseline 2. Broad VMT/VMA >1500 microns at baseline 3. History of vitrectomy/injections 4. History of laser photocoagulation to the macula in the study eye 5. High myopia 6. Aphakia 7. History of retinal detachment/breaks/Vitreous hemorrhage 8. Diabetic retinopathy, ischaemic retinopathies, retinal vein occlusio

Design outcomes

Primary

Measure	Time frame
Release of vitreomacular traction will be checked by using an optical coherence tomography at one week and four weeks postoperatively.	—

Secondary

Measure	Time frame
Visual acuity and central retinal thickness is measured using a Snellen chart and an optical coherence tomography at one and four weeks postoperatively.	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026